IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2018-06-01. The firm has sold all of its assets. The company is not engaged in any business operations.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for IMVIF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning IMVIF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: IMVIF is a Strong Buy candidate.
IMVIF stock price ended at $0 on 星期三, after rising NaN%
On the latest trading day Dec 24, 2025, the stock price of IMVIF rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 29.1K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.8K shares were traded, amounting to a market value of approximately --.